通心络胶囊对急性冠脉综合征患者C反应蛋白的干预

目的探讨急性冠脉综合征在常规治疗基础上加用通心络胶囊后C反应蛋白（CRP）的变化及其临床意义。方法采用前瞻性对照研究，将133例急性冠脉综合征患者随机分为治疗组67例和对照组66例，两组均予常规治疗，治疗组于入院后48h内加用通心络胶囊2粒、3次／d治疗。测定患者入院时、入院后4周、入院后8周的CRP水平变化。结果加用通心络胶囊可进一步降低急性冠脉综合征患者CRP水平，这种变化在治疗4周后即可显现，在治疗8周后更为明显。结论急性冠脉综合征患者早期联合应用通心络胶囊可进一步降低CRP水平。

Intervention of Tongxinluo Capsule on CRP in Patients with Acute Coronary Syndrome

Objective To investigate the change of C reactive protein(CRP) and its clinical significance in patients with acute coronary syndrome who receive Tongxinluo capsule on the basis of routine therapy.Methods The prospective and controlled trial was used.One hundred and thirty-three consecutive patients with acute coronary syndrome were randomly divided into Tongxinluo treatment group(67 cases) and control group(66 cases).Treatment group was taken Tongxinluo capsules,3 times per day,2 pills once in 48 h after admission.CRP was determined on admission and at 4 weeks after treatment and at 8 weeks after treatment.Results CRP further decreased in patients received additional Tongxinluo on the basis of routine therapy.The change was appeared after 4 weeks and more significantly after 8 weeks.Conclusion CRP can further decrease in patients received additional Tongxinluo capsules on the basis of routine therapy.